Summit Therapeutics Inc (NASDAQ: SMMT) Is An Investment You Should Consider If You’re A Risk Taker.

In the last trading session, 1.66 million Summit Therapeutics Inc (NASDAQ:SMMT) shares changed hands as the company’s beta touched -1.22. With the company’s per share price at $4.50 changed hands at $0.32 or 7.66% during last session, the market valuation stood at $3.14B. SMMT’s last price was a discount, traded about -4.89% off its 52-week high of $4.72. The share price had its 52-week low at $1.25, which suggests the last value was 72.22% up since then. When we look at Summit Therapeutics Inc’s average trading volume, we note the 10-day average is 1.89 million shares, with the 3-month average coming to 1.03.

Summit Therapeutics Inc (NASDAQ:SMMT) trade information

Instantly SMMT was in green as seen at the end of in last trading. With action 15.98%, the performance over the past five days has been green. The jump to weekly highs of 4.53 added 7.66% to the stock’s daily price. The company’s shares are showing year-to-date upside of 72.41%, with the 5-day performance at 15.98% in the green. However, in the 30-day time frame, Summit Therapeutics Inc (NASDAQ:SMMT) is 49.50% up. Looking at the short shares, we see there were 11.3 million shares sold at short interest cover period of 4.99 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Summit Therapeutics Inc (SMMT) estimates and forecasts

Year-over-year growth is forecast to reach -92.30% down from the last financial year. The company’s revenue for the corresponding quarters a year ago was $4.55 million and $192k respectively. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -0.32%.

Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 83.20% of Summit Therapeutics Inc shares while 4.84% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 28.82%. There are 4.84% institutions holding the Summit Therapeutics Inc stock share, with Blackrock Inc. the top institutional holder. As of Jun 29, 2023, the company held 1.26% of the shares, roughly 8.76 million SMMT shares worth $21.99 million.

Baker Brothers Advisors, LLC holds the second largest percentage of outstanding shares, with 0.90% or 6.3 million shares worth $15.82 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 3.66 million shares estimated at $9.19 million under it, the former controlled 0.52% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 0.38% of the shares, roughly 2.66 million shares worth around $4.31 million.

On Key

Related Posts